PALO ALTO, Calif.
March 21, 2013
/PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) announced that in the first week of
, the company launched a clinical trial for TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. The clinical trial, which is already in progress, is the result of collaboration between CBMG, California Stem Cell (CSC) and
's PLA 85 Hospital. It is the first immune cell clinical trial of its kind in
CBMG's joint venture with CSC grants CBMG an exclusive license from CSC to develop and market CSC's cancer (TC-DC) technology in
. CBMG receives support from CSC's
-based team of scientists and medical professionals, including CSC's Dr.
PLA 85 Hospital is a large general teaching hospital with 12 departments, located in
and has been granted Class A Hospital status at the Tertiary Level (the highest class). The hospital has over 600 beds with more than 200 professors and associate professors, including many well-known experts who are known for their pioneering work in the diagnosis and treatment of tumors. The principal Investigator of the trial and director of the Liver Disease Center of PLA 85 Hospital, Professor
, commented, "When I heard of the success this treatment had in clinical trials for other cancers in the U.S., I was very excited at the prospect of the hope it could bring to the millions of patients in
suffering from HCC. I am happy to lead this endeavor to help as many people as we can." Said Dr.
, Chairman of CBMG, "The launch of this trial is a major milestone for all of the physicians, scientists and other professionals at CBMG, CSC and PLA 85 Hospital who have contributed to this work."
Multinational Contract Research Organization (CRO) CMIC-GCP has been contracted to manage the trial design and minimize delays.